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1492 The Journal of Thoracic and CardUntil recently, the adult mammalian heart was considered a terminallydifferentiated organ incapable of regeneration. Remarkable observationaldata reported by Anversa and others challenged this dogma and postulated
that under appropriate circumstances, the myocardium does indeed have a limited
regenerative capacity secondary to a population of pluripotent stem cells.1,2 The last
several years have seen a flurry of research activity into the promise of stem cell
therapy for end-stage heart disease. The first clinical reports of feasibility further
encouraged investigation into this exciting new field.3 As with most new areas of
investigation, once the excitement surrounding the initial discovery wanes, the real
science begins.4
In this issue of the Journal, Patel and colleagues5 report preliminary data from a
prospective randomized trial in patients subjected to hybrid surgical revasculariza-
tion with or without autologous bone marrow–derived stem cell injections. The
authors are to be congratulated for providing the readership with one of the first
prospective surgical evaluations of this new therapy. The design of this trial was
carefully considered and should be discussed in more detail.
All patients underwent percutaneous coronary interventions to all diseased ter-
ritories apart from the left anterior descending coronary artery to avoid the con-
founding inflammatory effects of cardiopulmonary bypass. Patients were then
subjected to a full sternotomy and an off-pump left internal thoracic artery to left
anterior descending coronary artery anastomosis. In patients randomized to cell
therapy, approximately 500 mL of bone marrow was harvested from the iliac crest.
The authors claim that only a minimal number of puncture sites were required to
obtain this volume and that a minimum aspirate of 250 mL was required to continue
with the protocol. Apparently, all 10 patients randomized to cell therapy success-
fully yielded this minimum volume of marrow. The aspirate was then subjected to
centrifugation and purification to yield a population of cells that were more than
70% positive for CD34, a marker of endothelial lineage. The purified cell suspen-
sion was then diluted in 30 mL of the patient’s own plasma in preparation of
epicardial injection. The authors do not report the median time required to prepare
their cell concentrate but do admit to testing the limits of surgical patience
(R. Kormos, personal communication). A specialized injection needle was used that
lacked an end hole, enabling subepicardial injection with minimal leakage into the
pericardial cavity. An important methodological detail involved the injection of
cells only into viable or peri-infarct tissue and not directly into the center of obvious
myocardial scar. Importantly, no attempt was made to introduce an intracoronary
injection of cells. Also, the off-pump coronary artery bypass grafting (OPCAB)–
only group did not receive a placebo injection of plasma.
The primary end point of this study was the improvement in left ventricular
ejection fraction, as measured with transthoracic echocardiography. Although ad-
mittedly a weak assessment of ventricular function that is highly variable and load
dependent, the authors were able to demonstrate significant differences between
groups at 1 month that persisted until the 6-month follow-up. The magnitude of the
absolute difference in left ventricular ejection fraction is subtle at only 6% to 9%.
Interpreted another way, the OPCAB-only group demonstrated an improvement in
left ventricular ejection fraction of only 6% to 7%, whereas the OPCAB plus cell
transplantation group exhibited a 12% to 16% improvement. Importantly, no ad-
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injection of cells. This is in contrast to the earlier report by
Menasche and associates3 that raised concern about the
potential proarrhythmic effects of cell transplantation.
Again, as with any important study, the present report
raises more questions than it answers. Most experts now
agree that clinical cell transplantation can be performed
with minimal morbidity, yet the efficacy and the mechanism
of benefit remain unclear. An earlier award-winning study
by Chu and coworkers6 from McGill demonstrated that
needle puncture of the myocardium was equally as effica-
cious as transmyocardial laser revascularization. Is the
mechanism of benefit in this study solely a result of the
multiple needle punctures, or is there actual engraftment of
cells with transformation into angiogenic or myogenic tis-
sue? Is it important to purify the marrow aspirate to obtain
enriched CD34 cells, or is an unpurified suspension equally
efficacious? Can similar results be achieved in patients who
are placed on cardiopulmonary bypass, or does the resultant
inflammatory response impair the engraftment of the trans-
The Journal of Thoracicplanted cells? Can injection into the central scar area truly
regenerate infarcted myocardium, or is it necessary to inject
cell isolates into potentially viable tissue? Most of these
latter questions will be answered in future clinical trials by
this ambitious group of investigators. I applaud them for
their scientific rigor in applying a prospective randomized
approach to the evaluation of this exciting new therapy.
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